Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Morè, Sonia, Corvatta, Laura, Manieri, Valentina Maria, Saraceni, Francesco, Scortechini, Ilaria, Mancini, Giorgia, Fiorentini, Alessandro, Olivieri, Attilio, Offidani, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870632/
https://www.ncbi.nlm.nih.gov/pubmed/35203257
http://dx.doi.org/10.3390/cells11040606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870632/
https://www.ncbi.nlm.nih.gov/pubmed/35203257
http://dx.doi.org/10.3390/cells11040606

Ejemplares similares